Compare Stocks

BlackRock Enhanced Global Dividend Trust is a closed ended equity mutual fund launched by BlackRock, Inc. The fund is co-managed by BlackRock Advisors, LLC and BlackRock International Limited. It invests in public equity markets across the globe. The fund seeks to invest in stocks of companies operating across diversified sectors. It invests in stocks of companies across all market capitalizations. The fund also invests through derivatives, with an emphasis on options on equity securities or indices. It benchmarks the performance of its portfolio against the S&P Global Broad Market Index. The fund was formerly known as BlackRock Global Opportunities Equity Trust. BlackRock Enhanced Global Dividend Trust was formed on May 31, 2005 and is domiciled in the United States.

CH Energy Group, Inc., is the holding company. The Company's wholly owned subsidiaries include Central Hudson and Central Hudson Enterprises Corporation (CHEC). Central Hudson is a regulated electric and natural gas subsidiary. CHEC, the parent company of CH Energy Group's unregulated businesses and investments, has one wholly owned subsidiary, Griffith Energy Services, Inc. (Griffith). The Company operates in four segments: Central Hudson's regulated electric utility business; Central Hudson's regulated natural gas utility business; Griffith's fuel distribution business, and other businesses and investments, which includes CHEC's renewable energy investments and the holding company's activities, which consists of financing its subsidiaries. In June 2013, FortisBC Energy Inc completed its previously announced acquisition of CH Energy Group Inc.

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.